---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Mechanism of action"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Mechanism of action. Topics: Oncolytic immunotherapy with dual mechanisms of action, Serotype-5 adenovirus designed for selective replication in cells with retinoblastoma pathway alterations, Cell entry through coxsackievirus and adenovirus receptors, Tumor selectivity and the GM-CSF transgene as described by the manufacturer, and 2 further topics. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Oncolytic immunotherapy with dual mechanisms of action

> “Cretostimogene grenadenorepvec (hereafter, cretostimogene) is an oncolytic immunotherapy with dual mechanisms of action”
> “it replicates in and lyses cancer cells with retinoblastoma-E2F pathway alterations and amplifies the immune response”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-2.1.2.6.1-2"></a>

### Serotype-5 adenovirus designed for selective replication in cells with retinoblastoma pathway alterations

> “Cretostimogene grenadenorepvec is a serotype-5 oncolytic adenovirus designed to selectively replicate in cancer cells with retinoblastoma pathway alterations”

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)

<a id="topic-2.1.2.6.1-3"></a>

### Cell entry through coxsackievirus and adenovirus receptors

> “Cretostimogene is an investigational oncolytic immunotherapy that has been designed to selectively replicate in retinoblastoma (Rb)-E2F gene pathway-altered cells present in the majority of UCs and trigger an anti-tumor immune response.”
> “Cretostimogene enters the tumor by binding to Coxsackievirus and Adenovirus Receptors (CAR) present in specialized intracellular junctions and tight junctions of polarized epithelial cells.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.2.6.1-4"></a>

### Tumor selectivity and the GM-CSF transgene as described by the manufacturer

> “There are two modifications made to cretostimogene for tumor selectivity and potency.”
> “The first modification is the insertion of an E2F-1 promoter in cretostimogene which acts as a safety mechanism to selectively replicate and lyse Rb-E2F altered tumor cells rather than healthy cells which have intact Rb pathways.”
> “The second modification is the insertion of the gene for the cytokine granulocyte-macrophage colony stimulation factor (GM-CSF).”
> “GM-CSF is widely recognized as a potent stimulator of longer-term anti-tumor activity, and we believe its addition to the viral construct may both prime the immune system and induce tumor-specific immunity.”
> “Replication and lysis of Rb-E2F altered tumor cells by cretostimogene may trigger an immunogenic cell death that stimulates an anti-tumor immune response.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.2.6.1-5"></a>

### Functions attributed to the elements of the construct

| Element | Stated function |
| --- | --- |
| E2F | “Leads to selective viral replication in tumor cells, but not normal cells” |
| E1A / E3 | “Viral gene retains wild-type adenovirus lytic ability” |
| GM-CSF | “GM-CSF activates and matures antigen-presenting cells” |

Source: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

<a id="topic-2.1.2.6.1-6"></a>

### Direct lysis combined with immune-mediated cell death

> “The CG0070 mechanism of action includes direct cell lysis in conjunction with immune mediated cell death which is enhanced in the presence of GM-CSF.”
> “In CG0070, the human E2F-1 promoter drives expression of the essential viral genes and restricts viral replication to retinoblastoma (Rb) gene pathway defective tumor cells, selectively killing these cells with minimal damage to normal tissues.”

Source: [Li et al. (2021)](https://cgoncology.com/wp-content/uploads/2025/11/2021_sitc_core-001_poster-1.pdf)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
